Product Image
Please see full prescribing and safety information, including boxed warning, for  MITOMYCIN 5 mg, 20 mg and 40 mg single-dose vials.

Available in:

  • 5 mg per vial single-dose vials
  • 20 mg per vial single-dose vials
  • 40 mg per vial single-dose vials


  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

MITOMYCIN for Injection, USP*

Brand Name Equivalent: MUTAMYCIN® (MUTAMYCIN is a registered trademark of Accord Healthcare, Inc.)
Therapeutic Category: Antineoplastic Agent

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
Description Strength Fill
Concentration Container
Closure Unit
of Sale
250-20 Amber Glass Vial 5 mg N/A N/A 20 mL 20 mm 1
251-50 Amber Glass Vial 20 mg N/A N/A 50 mL 20 mm 1
252-51 Amber Glass Vial 40 mg N/A N/A 100 mL 20 mm 1
WARNING: Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin (see WARNINGS and ADVERSE REACTIONS sections). Hemolytic Uremic Syndrome (HUS) a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs, however, most cases occur at doses 60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined.